Clinical Trial

Phase 2A/B Efficacy and Safety of Dabogratinib in Participants With Low Grade Upper Tract Urothelial Carcinoma

Study acronym: SURF303
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
A Phase 2A/B study of Dabogratinib (TYRA-300) in Low Grade Upper Tract Urothelial Carcinoma
Protocol Amendment History 14 amendments
This ClinicalTrials.gov record has been amended 14 times since 2025-12-02; most recent amendment 2026-07-13.
Status change: Not Yet Recruiting → Recruiting 2026-01-15
Trial Details
NCT Number NCT07265947
Lead Sponsor Tyra Biosciences, Inc
Conditions Low Grade Upper Tract Urothelial Carcinoma
Enrollment 230 participants
Start Date 2025-12-22
Primary Completion 2030-10 (estimated)
Study Completion 2030-11 (estimated)
Updated on ClinicalTrials.gov 2026-08-03